Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-Myb genes in cutaneous T-cell lymphoma cells

Blood

Volumn 98, Issue 9, 2001, Pages 2778-2783

  Qin, Jian Zhong ^a   Zhang, Chun Lei ^a   Kamarashev, Jivko ^a   Dummer, Reinhard ^a   Burg, Günter ^a   Döbbeling, Udo ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 7; PROTEIN BCL 2; PROTEIN C MYB; STAT2 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ARTICLE; CELL DEATH; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE C MYB; PRIORITY JOURNAL; T CELL LYMPHOMA;

EID: 0035525783     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2778     Document Type: Article

References (48)

1. Burg G, Kempf W, Häffner AC, et al. Cutaneous lymphomas. Curr Probl Dermatol. 1997;9:139-204.
2. Dalloul A, Laroche L, Bagot M, et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest. 1992;90:1054-1060.
3. Döbbeling U, Dummer R, Laine E, Potoczna N, Qin J-Z, Burg, G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood. 1998;921:252-258.
4. Matsue H, Bergstresser PR, Takashima A. Keratinocyte-derived IL-7 serves as a growth factor for dendritic epidermal T cells in mice. J Immunol. 1993;151:6012-6019.
5. Mohamadzadeh M, Takashima A, Dougherty I, Knop J, Bergstresser PR, Cruz PD. Ultraviolet B radiation up-regulates the expression of IL-15 in human skin. J Immunol. 1995;155:4492-4496.
6. Blauvelt A, Asada H, Klaus-Kovtun V, Altman DJ, Lucey DR, Katz SI. Interleukin-15 mRNA is expressed by human keratinocytes, Langerhans cells, and blood derived dendritic cells and is down-regulated by ultraviolet B radiation. J Invest Dermatol. 1996;106:1047-1052.
7. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264:965-968.
8. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822-2830.
9. Girl JG, Kumaki S, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995;14:3654-3663.
10. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 1995;154:483-490.
11. Nowak R. Bubble boy paradox resolved [abstract]. Science. 1993;262:1818.
12. Miyazaki T, Liu ZJ, Kawahara A, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and Ick cooperate in hematopoietic cell proliferation. Cell. 1995;81:223-231.
13. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992;80:879-886.
14. Lee SH, Fujita N, Mashima T, Tsuruo T. Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression. Oncogene. 1996;13:2131-2139.
15. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
16. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285-291.
17. Osborne BA. Apoptosis and the maintenance of homeostasis in the immune system. Curr Opin Immunol. 1996;8:245-254.
18. Kanavaros P, Ioannidou D, Tzardi M, et al. Mycosis fungoides: expression of C-myc p62, p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus. Pathol Res Pract. 1994;190:767-774.
19. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol. 1995;22:11-17.
20. Frampton J, Ramquist T, Graf T. v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells. Genes Dev. 1996;10:2720-2731.
21. Taylor D, Badiani P, Weston K. A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev. 1996;10:2732-2744.
22. Salomoni P, Perrotti D, Martinez R, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of Bcl-2 expression and Myb-dependent regulation of bcl-2 promoter activity. Proc Natl Acad Sci U S A. 1997;94:3296-3301.
23. Weber-Nordt RM, Egen C, Wehinger J, et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996;88:809-816.
24. Roussel M, Saule S, Lagrou C, et al. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature. 1979;281:452-455.
25. Thompson CB, Challoner PB, Neiman PE, Groudine M. Expression of the c-myb proto-oncogene during cellular proliferation. Nature. 1986;319:374-380.
26. Wakao H, Gouilleux F, Groner, B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 1994;13:2182-2192.
27. Wakao H, Harada N, Kitamura T, Mui ALF, Miyajima A. Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO J. 1995;14:2527-2535.
28. Fujii H, Nakagawa Y, Schindler U, et al. Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci U S A. 1995;92:5482-5486.
29. Johnston JA, Bacon CM, Finbloom DS, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A. 1995;92:8705-8709.
30. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. Proc Natl Acad Sci U S A. 1996;93:9148-9153.
31. Schindler C, Darnell JE. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
32. Barberis A, Superti-Furga G, Busslinger M. Mutually exclusive interaction of the CCAAT-binding factor and of a displacement protein with overlapping sequences of a histone gene promoter. Cell. 1987;50:347-359.
33. Gerber HP, Georgiev O, Harshman K, Schaffner W. In vitro transcription complementation assay with miniextracts of transiently transfected COS-1 cells. Nucl Acids Res. 1992;20:5855-5856.
34. Dummer R, Heald PW, Nestle FO, et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88:1383-1389.
35. Garatti SA, Roscetti E, Trecca D, Fracchiolla NS, Neri A, Berti E. bcl-1, bcl-2, p53, c-myc, and lyt-10 analysis in cutaneous lymphomas. Recent Results Cancer Res. 1995;139:249-261.
36. Nicolaides NC, Gualdi R, Casadevall C, Manzella L, Calabretta B. Positive autoregulation of c-myb expression via Myb binding sites in the 5′ flanking region of the human c-myb gene. Mol Cell Biol. 1991;11:6166-6176.
37. Majello B, Kenyon LC, Dalla-Favera R. Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A. 1986;83:9636-9649.
38. Qin J-Z, Dummer R, Burg G, Döbbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood. 1999;93:260-267.
39. Qin J-Z, Kamarashev J, Zhang C-L, Dummer R, Burg G, Döbbeling U. Constitutive and IL-7 and IL-15 stimulated DNA-binding of STAT and novel factors in cutaneous t cell lymphoma (CTCL) cells. J Invest Dermatol. In press.
40. Bulfone-Paus S, Ungureanu D, Pohl T, et al. Interleukin-15 protects from lethal apoptosis in vivo. Nat Med. 1997;3:1124-1128.
41. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-7. J Exp Med. 1997;186:325-330.
42. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32.
43. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter life and death for T cells in vivo. Nat Med. 2001;7:114-118.
44. Takemoto S, Mulloy JC, Cereseto A, et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins [abstract]. Proc Natl Acad Sci U S A. 1997;94:13897.
45. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
46. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-928.
47. Starr R, Wilson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
48. Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T cell lymphoma. Blood. 2001;97:1056-1062.